FAQs
1. What is the life expectancy for someone diagnosed with lupus?
With modern medical interventions, most individuals can expect a near-normal lifespan. Roughly 80% to 90% of patients live at least ten years after their initial diagnosis. While severe organ involvement can pose life-threatening risks, early detection and consistent management have transformed lupus from a fatal condition into a manageable chronic illness.
2. Can women with lupus safely have children?
Most women can have successful pregnancies, provided the disease is in remission for at least six months before conception. These are typically managed as high-risk pregnancies to monitor for complications like preeclampsia. Some babies may develop neonatal lupus, but this is usually a temporary condition that resolves within a few months.
3. Is lupus a hereditary disease that I will pass to my children?
Lupus is not directly inherited like some genetic disorders; therefore, having the disease does not guarantee your children will develop it. While family history increases susceptibility, the actual risk for a child is only about 5%. It usually requires a specific combination of many different genes and environmental triggers to manifest.
Reference
1. Chatterjee, R., & Aggarwal, A. (2023). Challenges in the diagnosis and management of SLE in India. Clinical Immunology Communications, 4, 65-69.
2. Gillmore, R., & Sin, W. Y. C. (2014). Systemic lupus erythematosus mimicking lymphoma: the relevance of the clinical background in interpreting imaging studies. Case Reports, 2014, bcr2013201802.
3. Xu, L., Su, X., Liu, Z., et al. (2022). Predicted Immune‐Related Genes and Subtypes in Systemic Lupus Erythematosus Based on Immune Infiltration Analysis. Disease Markers, 2022(1), 8911321.
4. Barbhaiya, M., & Costenbader, K. H. (2016). Environmental Exposures and the Development of Systemic Lupus Erythematosus. Current opinion in rheumatology, 28(5), 497.
5. Barbhaiya, M., & Costenbader, K. H. (2014). Ultraviolet radiation and systemic lupus erythematosus. Lupus, 23(6), 588-595.
6. Iwata, S., & Tanaka, Y. (2022). Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Frontiers in medicine, 9, 849120.
7. Lichtnekert, J., & Anders, H. J. (2024). Lupus nephritis-related chronic kidney disease. Nature reviews rheumatology, 20(11), 699-711.
8. Svenungsson, E., Jensen-Urstad, K., Heimbürger, M., et al. (2001). Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation, 104(16), 1887-1893.
9. Nashi, E., Wang, Y., & Diamond, B. (2010). The role of B cells in lupus pathogenesis. The international journal of biochemistry & cell biology, 42(4), 543-550.
10. Di Matteo, A., Smerilli, G., Cipolletta, E., et al. (2021). Imaging of joint and soft tissue involvement in systemic lupus erythematosus. Current rheumatology reports, 23(9), 73.
11. Zeĉević, R. D., Vojvodić, D., Ristić, B., et al. (2001). Skin lesions-an indicator of disease activity in systemic lupus erythematosus?. Lupus, 10(5), 364-367.
12. Herrada, A. A., Escobedo, N., Iruretagoyena, M., et al. (2019). Innate immune cells’ contribution to systemic lupus erythematosus. Frontiers in immunology, 10, 772.
13. Niewold, T. B. (2011). Interferon alpha as a primary pathogenic factor in human lupus. Journal of interferon & cytokine research, 31(12), 887-892.
14. Patiño-Martinez, E., & Kaplan, M. J. (2025). Immunometabolism in systemic lupus erythematosus. Nature Reviews Rheumatology, 21(7), 377-395.
15. Podolska, M. J., Biermann, M. H., Maueröder, C., et al. (2015). Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. Journal of inflammation research, 8(2015), 161-171.
16. Arneth, B. (2019). Systemic lupus erythematosus and DNA degradation and elimination defects. Frontiers in Immunology, 10, 1697.
17. Macedo, A. C. L., & Isaac, L. (2016). Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Frontiers in immunology, 7, 55.
18. Ma, L., & Morel, L. (2022). Loss of gut barrier integrity in lupus. Frontiers in immunology, 13, 919792.
19. Zhou, J., Lei, B., Shi, F., et al. (2024). CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology, 15, 1476859.
20. Askanase, A., Shum, K., & Mitnick, H. (2012). Systemic lupus erythematosus: an overview. Social work in health care, 51(7), 576-586.
21. Corbin, D., Christian, L., Rapp, C. M., et al. (2023). New concepts on abnormal UV reactions in systemic lupus erythematosus and a screening tool for assessment of photosensitivity. Skin research and technology, 29(3), e13247.
22. Chanprapaph, K., Udompanich, S., Visessiri, Y., et al. (2019). Nonscarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses. Journal of the American Academy of Dermatology, 81(6), 1319-1329.
23. Heimovski, F. E., Simioni, J. A., & Skare, T. L. (2015). Systemic lupus erythematosus and Raynaud’s phenomenon. Anais Brasileiros de Dermatologia, 90(6), 837.
24. Dehghan, A., Soltani, H., Faezi, S. T., et al. (2023). Depression, anxiety, and quality of life in patients with systemic lupus erythematosus. Reumatologia, 61(5), 368.
25. Ahn, G. E., & Ramsey-Goldman, R. (2012). Fatigue in systemic lupus erythematosus. International journal of clinical rheumatology, 7(2), 217.
26. Mackay, M. (2015). Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus. Immunologic research, 63(1), 26-37.
27. Cheng, S., Ding, H., Xue, H., et al. (2022). Evaluation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in children and adults. Clinical Rheumatology, 41(10), 2995-3003.
28. Pisetsky, D. S. (2017). Antinuclear antibody testing—misunderstood or misbegotten?. Nature Reviews Rheumatology, 13(8), 495-502.
29. Ahn, S. S., Jung, S. M., Yoo, J., et al. (2019). Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatology international, 39(11), 1937-1944.
30. Walport, M. J. (2002). Complement and systemic lupus erythematosus. Arthritis research & therapy, 4(Suppl 3), S279.
31. Chedid, A., Rossi, G. M., Peyronel, F., et al. (2020). Low-level proteinuria in systemic lupus erythematosus. Kidney International Reports, 5(12), 2333-2340.
32. Al-Zahir, M. Z., & Chan, K. L. (2024). Echocardiography in systemic lupus erythematosus. Current Cardiology Reports, 26(11), 1265-1271.
33. Lins, C. F., & Santiago, M. B. (2015). Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review. European radiology, 25(9), 2688-2692.
34. Lozovoy, M. A. B., Simao, A. N. C., Hohmann, M. S. N., et al. (2011). Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus, 20(13), 1356-1364.
35. Wu, T., Xie, C., Han, J., et al. (2012). Metabolic disturbances associated with systemic lupus erythematosus. PloS one, 7(6), e37210.
36. Littlejohn, E., Marder, W., Lewis, E., et al. (2018). The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus, 27(7), 1123-1129.
37. Xuan, J., Deng, C., Lu, H., et al. (2025). Serum lipid profile in systemic lupus erythematosus. Frontiers in Immunology, 15, 1503434.
38. Carranza-Leon, D. A., Oeser, A., Wu, Q., et al. (2020). Ambulatory blood pressure in patients with systemic lupus erythematosus: association with markers of immune activation. Lupus, 29(13), 1683-1690.
39. Harper, L., Ardoin, S. P., Leever, A., et al. (2024). Automated mental health screening in pediatric lupus: associations with disease features and treatment. Frontiers in pediatrics, 12, 1427543.
40. Taylor Meadows, K. R., Steinberg, M. W., Clemons, B., et al. (2018). Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One, 13(4), e0193236.
41. Islam, M. A., Khandker, S. S., Kotyla, P. J., et al. (2020). Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): a systematic review. Frontiers in immunology, 11, 1477.
42. Blaess, J., Goepfert, T., Geneton, S., et al. (2023, February). Benefits & risks of physical activity in patients with Systemic Lupus Erythematosus: a systematic review of the literature. In Seminars in arthritis and rheumatism (Vol. 58, p. 152128). WB Saunders.
43. Rossato, S., Oakes, E. G., Barbhaiya, M., et al. (2025). Ultraprocessed food intake and risk of systemic lupus erythematosus among women observed in the Nurses’ Health Study cohorts. Arthritis care & research, 77(1), 50-60.
44. Ponticelli, C., & Moroni, G. (2017). Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert opinion on drug safety, 16(3), 411-419.
45. Broen, J. C., & van Laar, J. M. (2020). Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nature Reviews Rheumatology, 16(3), 167-178.
46. Wang, D., Wang, X., Tan, B., et al. (2025). Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med, 6(10).
47. Kahwaji, N., Kotzian, N., Prinz, J. M., et al. (2026). mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells. Molecular Therapy Nucleic Acids, 37(1), 102805.
48. Thurman, J. M., & Serkova, N. J. (2015). Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research, 4, 153.